MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is Canvuparatide (MBX 2109), a parathyroid hormone peptide prodrug, which is in Phase 3 clinical trial for the treatment of chronic hypoparathyroidism. The company is also developing Imapextide (MBX 1416), a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 2 clinical trial a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies for the treatment of obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.
Frequently asked questions
What sector does MBX (MBX) operate in?
MBX belongs to the Healthcare sector and operates in the Biotechnology industry.
What is MBX (MBX) current stock price?
As of the latest data, MBX stock price is $50.29, with a previous close of $48.50. MBX gained $1.79 in the last trading session, representing a 3.69% increase.
What is MBX (MBX) current market capitalization?
MBX market cap is approximately 2.42 billion.
What is MBX (MBX) Earnings Per Share (EPS)?
The trailing EPS is -$2.37, and the forward EPS is -$3.98.
What is MBX (MBX) EBITDA?
MBX EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -40.85 million.
Does MBX (MBX) pay dividends?
No. MBX does not pay a dividend.
When is MBX (MBX) next earnings report?
MBX is expected to release its next earnings report on September 30, 2026.
What is MBX (MBX) beta (volatility) score?
MBX has a beta of 0.103, indicating lower volatility than the overall market.
